摘要
目的:本实验研究索拉非尼对Hela细胞相关活性的影响,为该药物的临床应用提供理论依据。方法:我们通过MTT实验和Edu增殖实验研究索拉非尼对Hela细胞增殖能力的影响,分别通过划痕实验以及Transwell小室侵袭实验研究索拉非尼作用后Hela细胞迁移能力和侵袭能力的变化。结果:在MTT实验中5、10和20μmol/L索拉非尼刺激48小时后Hela细胞的OD值均显著小于对照组(P<0.05)。10μmol/L药物刺激后Hela细胞的Edu阳性数量和比例均显著小于对照组(P<0.05)。在细胞划痕实验中,药物组细胞的迁移能力显著减弱,空白划痕两侧的距离显著大于对照组(P<0.05)。在Transwell小室侵袭实验中,药物组单个视野内的细胞数量显著少于对照组(P<0.01)。结论:索拉非尼可以抑制Hela细胞增殖、迁移和侵袭能力,是一种对抗宫颈癌细胞活性的潜在药物。
Objective： To study the effect of sorafenib on proliferation,migration and invasion in Hela cell line.Methods： MTT assay and Edu stain were used as assess proliferation of Hela cell. Erasion trace test and Transwell invasion assay were used as evaluate cell migration and invasion. Results： In MTT assay,OD values of Hela cells treated with 5,10 and 20 μmol/L sorafenib for 48 h were significantly lower than that of control cells. The number and rate of edu positive cells were significantly less in sorafenib treated cells than in control cells. In erasion trace test,cells treated with sorafenib migrated much slow than control cells. The distance of cells in the wound region was significantly shorter in sorafenib treated wells than that in control cells. In Transwell invasion assay the number of cells on the lower surface of the inserts in sorafenib treated cells was much less than that in control cells. Conclusion： Sorafenib inhibited proliferation,migration and invasion in Hela cell line. It was a kind of potential drugs against cervical cancer cell activity.
出处
《现代肿瘤医学》
CAS
2017年第12期1879-1883,共5页
Journal of Modern Oncology
